Neoadjuvant targeted therapy for BRAF-mutant colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that is locally advanced or has limited spread to other organs (resectable metastases).
- Your tumor has the BRAF V600E mutation and is mismatch repair proficient (pMMR/MSS), with no NRAS or KRAS mutations.
- You have not received prior systemic treatment for your colorectal cancer, and if you have metastatic disease, you have not had targeted therapy.
- Your blood counts, liver and kidney function, and heart function are within specified limits (e.g., hemoglobin ≥ 90 g/L, adequate platelets, LVEF ≥ 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has a specific genetic change called BRAF V600E. The treatment includes a targeted therapy (ivosidenib) plus chemotherapy and a pain-relief drug (celecoxib). It is for people whose cancer has stopped responding to previous treatments, including BRAF-targeted therapies.
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new combination of drugs (an immunotherapy called QL1706 plus bevacizumab and standard chemotherapy) as a first-line treatment for people with advanced colorectal cancer that has a BRAF V600E mutation. The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.